Novel molecular glue degrader therapy reaches first patients
Neomorph has commenced a Phase I/II clinical trial evaluating NEO-811, a novel investigational molecular glue degrader, in patients with locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC). NEO-811 is an investigational molecular glue degrader designed to induce targeted degradation of a key disease-driving protein… Read More